AI-powered Bioreactors to Revolutionize Biopharmaceutical Manufacturing
Toronto, Kitchener, Ontario and United Kingdom – July 24, 2025 – In a transformative step toward next-generation biopharmaceutical manufacturing, Basetwo is a key collaborator in the AI-driven innovation in the BALANCE collaboration. This pioneering project will leverage AI, automation, and real-time sensing to optimize biologics manufacturing, helping to reduce inefficiencies and accelerate the path to market. The BALANCE (Bioreactor Automation for Learning and Adaptive Networked Control of Experiments) platform is being developed through a collaborative effort with CPI, Labman Automation, and Nicoya, with AI development powered by Basetwo.
The 20-month project, funded by a $2 million grant from Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), integrates real-time sensing, control systems, and bioreactor technologies into a seamless platform designed to make biologics production smarter, faster, and more efficient. Central to this innovation is Basetwo’s digital twin technology, which will help ensure higher yields, improved scalability, and lower production costs.
Biopharmaceutical manufacturing often suffers from inefficiencies, particularly in the upstream bioprocessing phase. Optimizing bioreactor performance is crucial to overcoming these challenges. The BALANCE project will address these inefficiencies through a closed-loop AI control system powered by Basetwo’s advanced digital twin platform. By interpreting real-time data from bioreactors and biosensors, Basetwo’s AI models will enable adaptive control of experimental conditions, allowing for dynamic optimization of the bioprocess.
Basetwo’s platform integrates hybrid modeling techniques that predict quality outcomes, which reduces reliance on costly and time-consuming lab testing. This predictive capability significantly enhances both efficiency and cost-effectiveness in biologics manufacturing. The collaboration also involves Labman Automation’s modular sampling platform, which automates molecular analysis in conjunction with Nicoya’s Alto SPR biosensor, providing instant yield data for real-time adjustments.
“We’re proud to be at the forefront of this breakthrough project, as AI-enabled digital twins have the potential to redefine biomanufacturing,” said Thouheed Abdul Gaffoor, CEO at Basetwo. “By leveraging our hybrid modeling approach and combining it with cutting-edge sensing and automation, this collaboration takes us one step closer to autonomous, smarter biomanufacturing, with significant reductions in both time and cost for life-saving therapeutics.”
The goal of the BALANCE collaboration is to create an AI-optimized demonstrator platform that enhances the precision and efficiency of biologic drug production. With CPI focused on validating and scaling the platform for practical use, the project aims to drive down costs, reduce variability, and accelerate the timeline for bringing biologic therapeutics to market.
About Basetwo
Basetwo is an AI platform helping process engineers in pharmaceutical and chemical manufacturing optimize operations using hybrid modelling. The platform provides engineers with recommendations on the next best action they can implement to maximize product quality, production yield, and process efficiency.
For more information about Basetwo, or for media inquiries please contact:
Victoria Galimanis
Inbound Marketing Lead
victoria@basetwo.ai
